

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
10 November 2005 (10.11.2005)

PCT

(10) International Publication Number
WO 2005/105186 A1

(51) International Patent Classification⁷: **A61M 15/00**

(21) International Application Number:
PCT/EP2005/051992

(22) International Filing Date: 2 May 2005 (02.05.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
20 2004 007 115.0 3 May 2004 (03.05.2004) DE

(71) Applicant (for all designated States except US): **ALTANA PHARMA AG** [DE/DE]; Byk-Gulden-Str. 2, 78467 Konstanz (DE).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **PFEIFFER, Jutta** [DE/DE]; Eichenweg 11, 88085 Langenargen (DE).

(74) Agents: **KRATZER, Bernd** et al.; c/o ALTANA Pharma AG, Byk-Gulden-Str. 2, 78467 Konstanz (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only


Published:

- with international search report

[Continued on next page]

(54) Title: BLINDING DEVICE

(57) Abstract: The present invention relates to a cap (1) which is placed onto an aerosol container (2) in order to permit blinding of clinical studies.



WO 2005/105186 A1



-
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

Blinding device

Technical field of the invention

The invention relates to a device which permits blinding of a pressurized container for inhalation.

Prior art

Many active substances for treatment of diseases of the airways, such as asthma, are provided as preparations in pressurized containers from which they are administered into the lungs. Such a pharmaceutical product is made up, for example, of an aerosol container (pressurized container), which has a dispensing valve, and of a mouthpiece in which the container is received. The valve stem of the dispensing valve is received in a nozzle section of the mouthpiece.

The bases of the aerosol containers which hold test medication and which are used in clinical studies often have imprints which allude to the nature of the product or to the manufacturer and which could thus lead to unblinding of the study. When conducting clinical studies with such products, it is therefore necessary to make the bases unviewable, i.e. to ensure blinding of the product.

This has hitherto been achieved mainly by covering the bases with materials such as adhesive or talcum powder. However, this method proves very problematic because the blinding has to be done manually, thus taking up a great deal of time (manual mixing and setting of the adhesive). The correct mixing ratio with talcum powder is also difficult to obtain, and this in practice also results in products of non-uniform appearance and in high reject rates. Vapours given off by the adhesives also make the blinding process very unpleasant.

DD 255260 is related to the blinding of vials containing sterile pharmaceutical compositions such as solutions, suspensions, freeze-dried products or powdered products.

US 6544250 is related to a device for blinding the administration of nonsolid pharmaceutical administration forms. The device is in particular an opaque container which has at least two attachments, one of which is intended for connection to a dispenser for the pharmaceutical administration form, and the other of which is intended for connection to an applicator, the inside of said container having means for holding back the pharmaceutical administration form.

- 2 -

Disclosure of the invention

The object of the present invention is to make available a blinded product which comprises an aerosol container, can be produced in a simple manner and avoids the abovementioned disadvantages of previous products.

According to the invention, the object is achieved by an opaque cap which is placed with an exact fit onto the base of the aerosol container and whose inner edge automatically wedges with the aerosol container when fitted.

The subject of the invention is therefore a pharmaceutical product comprising an aerosol container, a cap being placed with a form fit onto the base of the aerosol container, and its inner edge automatically wedging with the aerosol container.

Further embodiments according to the invention are set out in the patent claims.

The aerosol container is preferably a pressurized container with a dispensing valve at the end directed away from the base.

The pharmaceutical product preferably comprises a mouthpiece in which the aerosol container is received.

According to the invention, the cap is preferably a cap made of metal, for example stainless steel. However, other materials such as plastic are also conceivable. Production is by methods known to the skilled person, for example by deep-drawing of sheet-metal strips using a suitable drawing and cutting tool.

According to the invention, the cap is designed as a hollow cylinder which is open at one end and has an opaque base at the other end. According to the invention, the height of the cap is preferably chosen such that, when the aerosol is actuated (pressed down), the space between mouthpiece and pressurized container is not changed. This is important to ensure that the required air stream for the inhalation process is not impaired.

According to the invention, the cap has an internal diameter narrowing slightly in the direction of the open end of the cap. The cap can then be placed onto the base of the aerosol container by means of a slight pressure. The internal diameter of the cap narrowing slightly in the direction of the open end of the cap permits automatic, preferably irreversible wedging of the cap on the

- 3 -

aerosol container. It is in this way possible to ensure permanent adherence of the cap over the base of the aerosol container.

The dimensions of the cap depend on the size of the pressurized container to be covered. The cap according to the invention preferably has a height of 3 to 10 mm, preferably 4 to 6 mm, and an internal diameter in the range of 19 to 25 mm, preferably 21 to 23 mm.

Illustrative embodiments of the invention are explained in more detail with reference to the drawings, in which:

Fig. 1 shows a cap (1), according to the invention, made of stainless steel. The cap has a height of 5 mm and an internal diameter of 22.1 mm.

Fig. 2 shows an aerosol container (2) with dispensing valve (3) and fitted cap (1) (cross section).

Fig. 3 shows an aerosol container (2) with fitted cap (1) in a mouthpiece (4) (cross section).

- 4 -

Patent Claims

1. Pharmaceutical product comprising an aerosol container, a cap with an opaque base being placed with a form fit onto the base of the aerosol container, and the inner edge of the cap automatically wedging with the aerosol container.
2. Pharmaceutical product according to Claim 1, in which the aerosol container is a pressurized container with a dispensing valve at the end directed away from the base.
3. Pharmaceutical product according to Claim 1, in which the cap is made of metal.
4. Pharmaceutical product according to Claim 1, in which the cap is designed as a hollow cylinder which is open at one end and has an opaque base at the other end.
5. Pharmaceutical product according to Claim 4, in which the cap has an internal diameter narrowing slightly in the direction of the open end of the cap.
6. Pharmaceutical product according to Claim 4, in which the cap has a height of 3 to 10 mm, preferably 4 to 6 mm, and an internal diameter in the range of 19 to 25 mm, preferably 21 to 23 mm.
7. Pharmaceutical product according to Claim 6, in which the cap has a height of 5 mm and an internal diameter of 22.1 mm.
8. Pharmaceutical product according to Claim 2, additionally having a mouthpiece in which the aerosol container is received.




Fig 1

2/3




Fig 2




Fig 3

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2005/051992

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61M15/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61M A61J

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X A	WO 96/39337 A (SENETICS, INC) 12 December 1996 (1996-12-12) page 17, line 8 - line 25 -----	1,2,4,5, 8 6,7
X A	US 2003/178020 A1 (SCARROTT PETER MYKOLA) 25 September 2003 (2003-09-25) paragraph '0093! - paragraph '0095! -----	1,2,4,8 5-7
X A	WO 2004/022127 A (RIC INVESTMENTS, INC) 18 March 2004 (2004-03-18) page 6, line 19 - line 22 -----	1,2,4,8 5-7
A	US 5 368 016 A (HENRY ET AL) 29 November 1994 (1994-11-29) column 4, line 1 - column 6, line 34 -----	1,2,4-8
A	WO 96/26755 A (MARR, CHRISTOPH, THOMAS) 6 September 1996 (1996-09-06) page 4, line 16 - line 22 -----	1,2,8

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

19 July 2005

Date of mailing of the international search report

07/10/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Kroeders, M

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2005/051992

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9639337	A	12-12-1996	US 5718355 A	17-02-1998
			AU 5969796 A	24-12-1996
			IL 118593 A	31-10-2000
			WO 9639337 A1	12-12-1996
			ZA 9604642 A	08-07-1997
US 2003178020	A1	25-09-2003	AU 2003214492 A1	08-10-2003
			CA 2480035 A1	02-10-2003
			EP 1490135 A1	29-12-2004
			WO 03080162 A1	02-10-2003
WO 2004022127	A	18-03-2004	US 2004084045 A1	06-05-2004
			AU 2003265869 A1	29-03-2004
			WO 2004022127 A2	18-03-2004
US 5368016	A	29-11-1994	NONE	
WO 9626755	A	06-09-1996	AU 4729596 A	18-09-1996
			EP 0812219 A1	17-12-1997
			WO 9626755 A1	06-09-1996
			GB 2313787 A ,B	10-12-1997